Absence of transplacental passage of the low molecular weight heparin enoxaparin

Haemostasis

Volumn 30, Issue 5, 2000, Pages 243-248

  Dimitrakakis, Constantine ^a,b   Papageorgiou, Panayiotis ^a   Papageorgiou, Ioannis ^a   Antzaklis, Aris ^a   Sakarelou, Nafsika ^a   Michalas, Stylianos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Enoxaparin; Heparin, low molecular weight; Placenta

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD PLACENTA BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETUS CIRCULATION; HUMAN; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0034467025     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054140     Document Type: Article

References (21)

1. Haemostasis and coagulation disorders in pregnancy
2. Low molecular weight heparins and their use in obstetrics and gynecology
3. Low molecular weight heparin novo (LHN-1) does not cross the placenta during the second trimester of pregnancy
4. Low molecular weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
5. Use of low molecular weight heparin in pregnancy
6. Can low molecular weight heparin be used in pregnant women?
7. Safety of low-molecular-weight heparin in pregnancy: A systematic review
8. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - Administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
9. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia
10. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 101690)
11. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
12. Use of low molecular weight heparin for prophylaxis and treatment in pregnancy
13. Optimal management of pregnant women with acute venous thromboembolism
14. The special case of venous thromboembolism in pregnancy
15. Toxic and mutagenic effects of a low molecular weight heparin in rats
16. Absence of transplacental passage of Fraxiparin (low molecular weight heparin) during the 3rd trimester of pregnancy
17. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound
18. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
19. Prevention of post-operative venous thrombosis: A randomized trial comparing unfractioned heparin with low molecular weight heparin in patients undergoing total hip replacement
20. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
21. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients